Cardinal Health, Inc. 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the fiscal quarter and nine months ended March 31, 1996. Cardinal Health, Inc. operates as a drug wholesaler. The financial statements have been restated to reflect the pooling-of-interests merger with Medicine Shoppe International, Inc., effective November 13, 1995. On February 7, 1996, the Company announced a definitive merger agreement with Pyxis Corporation.
Key Financial Metrics
| Metric | Quarter Ended Mar 31, 1996 | Nine Months Ended Mar 31, 1996 |
|---|---|---|
| Net Revenues | $2,202,804,000 | $6,381,569,000 |
| Gross Margin | $150,926,000 (6.85%) | $417,432,000 (6.54%) |
| Operating Earnings | $66,809,000 | $146,599,000 |
| Net Earnings | $36,797,000 | $79,003,000 |
| Diluted EPS | $0.75 | $1.61 |
| Cash and Equivalents | $114,479,000 | $114,479,000 (Ending Balance) |
| Working Capital | $731,600,000 | $731,600,000 |
| Long-Term Debt | $257,943,000 | $257,943,000 |
Note: All figures in thousands except per share amounts and percentages.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 10% for the quarter and 9% for the nine-month period compared to the prior year. Growth was driven by internal wholesaling activities, new customers in managed care/chain sectors, and price increases.
- Merger Costs: A nonrecurring charge of approximately $16.4 million ($11.8 million net of tax) was recorded in the second quarter of fiscal 1996 related to the Medicine Shoppe merger. This included transaction fees and costs for integrating operations.
- Excluding Merger Costs: On a pro forma basis excluding Medicine Shoppe merger costs, operating earnings for the nine months ended March 31, 1996, would have been $162,973,000 (2.55% margin) and net earnings would have been $90,803,000 ($1.85 EPS).
- Liquidity: Working capital increased to $731.6 million from $636.0 million at June 30, 1995, driven by inventory and receivable growth offset by increased accounts payable and debt.
Guidance, Outlook, and Risks
- Capital Resources: The Company sold $150 million of 6% Notes due 2006 in January 1996. Management believes capital resources are adequate for anticipated expenditures and debt service.
- Pyxis Merger: The Company plans to issue approximately 15.0 million shares to acquire Pyxis Corporation. Shareholder approval was obtained on April 26, 1996.
- Legal Proceedings:
- Antitrust Litigation: Cardinal and Whitmire are defendants in consolidated class action antitrust lawsuits regarding brand name prescription drug pricing. Summary judgment was granted in favor of the defendants on April 4, 1996, though plaintiffs plan to appeal. The Company does not expect a material adverse effect.
- Pyxis Stockholder Actions: Four class action lawsuits were filed challenging the Pyxis merger terms. The Company believes these claims are without merit.
- Whitmire Merger Costs: Remaining estimated costs for the 1994 Whitmire merger are approximately $1.7 million, expected to be expended in fiscal 1996.
Investor Verification Checklist
- Verify the pro forma financial impact of the Medicine Shoppe merger costs ($16.4 million charge) on operating margins.
- Confirm the status of the Pyxis Corporation merger and the potential dilution from the issuance of 15.0 million shares.
- Monitor the appeal of the summary judgment in the Brand Name Prescription Drug Litigation.
- Review the timing of seasonal inventory purchases and their impact on cash flow from operations (net cash used in operating activities was $54.6 million for the nine months).
- Assess the utilization of the $150 million proceeds from the 6% Notes issued in January 1996.